1
|
Phuah JY, Maas BM, Tang A, Zhang Y, Caro L, Railkar RA, Swanson MD, Cao Y, Li H, Roadcap B, Catchpole AP, Aliprantis AO, Vora KA. Quantification of clesrovimab, an investigational, half-life extended, anti-respiratory syncytial virus protein F human monoclonal antibody in the nasal epithelial lining fluid of healthy adults. Biomed Pharmacother 2023; 169:115851. [PMID: 37976891 DOI: 10.1016/j.biopha.2023.115851] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2023] [Revised: 10/25/2023] [Accepted: 11/05/2023] [Indexed: 11/19/2023] Open
Abstract
BACKGROUND Clesrovimab (MK-1654) is an investigational, half-life extended human monoclonal antibody (mAb) against RSV F glycoprotein in clinical trials as a prophylactic agent against RSV infection for infants. METHODS This adult study measured clesrovimab concentrations in the serum and nasal epithelial lining fluid (ELF) to establish the partitioning of the antibody after dosing. Clesrovimab concentrations in the nasal ELF were normalized for sampling dilution using urea concentrations from ELF and serum. Furthermore, in vitro RSV neutralization of human nasal ELF following dosing was also measured to examine the activity of clesrovimab in the nasal compartment. FINDINGS mAbs with YTE mutations are reported in literature to partition ∼1-2 % of serum antibodies into nasal mucosa. Nasal: serum ratios of 1:69-1:30 were observed for clesrovimab in two separate adult human trials after urea normalization, translating to 1.4-3.3 % of serum concentrations. The nasal PK and estimates of peripheral volume of distribution correlated with higher extravascular distribution of clesrovimab. These higher concentration of the antibody in the nasal ELF corroborated with the nasal sample's ability to neutralize RSV ex vivo. An overall trend of decreased viral plaque AUC was also noted with increasing availability of clesrovimab in the nasal ELF from a human RSV challenge study. INTERPRETATION Along with its extended half-life, the higher penetration of clesrovimab into the nasal epithelial lining fluid and the associated local increase in RSV neutralization activity could offer infants better protection against RSV infection.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | - Yu Cao
- Merck & Co., Inc., Rahway, NJ, USA
| | | | | | | | | | | |
Collapse
|
2
|
Nussbaum J, Cao X, Railkar RA, Sachs JR, Spellman DS, Luk J, Shaw CA, Cejas PJ, Citron MP, Al-Ibrahim M, Han D, Pagnussat S, Stoch SA, Lai E, Bett AJ, Espeseth AS. Evaluation of a stabilized RSV pre-fusion F mRNA vaccine: Preclinical studies and Phase 1 clinical testing in healthy adults. Vaccine 2023; 41:6488-6501. [PMID: 37777449 DOI: 10.1016/j.vaccine.2023.05.062] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2023] [Revised: 05/15/2023] [Accepted: 05/26/2023] [Indexed: 10/02/2023]
Abstract
Human respiratory syncytial virus (RSV) causes a substantial proportion of respiratory tract infections worldwide. Although RSV reinfections occur throughout life, older adults, particularly those with underlying comorbidities, are at risk for severe complications from RSV. There is no RSV vaccine available to date, and treatment of RSV in adults is largely supportive. A correlate of protection for RSV has not yet been established, but antibodies targeting the pre-fusion conformation of the RSV F glycoprotein play an important role in RSV neutralization. We previously reported a Phase 1 study of an mRNA-based vaccine (V171) expressing a pre-fusion-stabilized RSV F protein (mDS-Cav1) in healthy adults. Here, we evaluated an mRNA-based vaccine (V172) expressing a further stabilized RSV pre-fusion F protein (mVRC1). mVRC1 is a single chain version of RSV F with interprotomer disulfides in addition to the stabilizing mutations present in the mDS-Cav1 antigen. The immunogenicity of the two mRNA-based vaccines encoding mVRC1 (V172) or a sequence-optimized version of mDS-Cav1 to improve transcriptional fidelity (V171.2) were compared in RSV-naïve and RSV-experienced African green monkeys (AGMs). V172 induced higher neutralizing antibody titers than V171.2 and demonstrated protection in the AGM challenge model. We conducted a Phase 1, randomized, placebo-controlled, clinical trial of 25 μg, 100 μg, 200 μg, or 300 μg of V172 in healthy older adults (60-79 years old; N = 112) and 100 μg, 200 μg, or 300 μg of V172 in healthy younger adults (18-49 years old; N = 48). The primary clinical objectives were to evaluate the safety and tolerability of V172, and the secondary objective was to evaluate RSV serum neutralization titers. The most commonly reported solicited adverse events were injection-site pain, injection-site swelling, headache, and tiredness. V172 was generally well tolerated in older and younger adults and increased serum neutralizing antibody titers, pre-fusion F-specific competing antibody titers, and RSV F-specific T-cell responses.
Collapse
Affiliation(s)
| | - Xin Cao
- Merck & Co., Inc., Rahway, NJ, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
3
|
Rosenbloom DIS, Dudášová J, Davis C, Railkar RA, Mehrotra N, Sachs JR. Replicate Testing of Clinical Endpoints Can Prevent No-Go Decisions for Beneficial Vaccines. Vaccines (Basel) 2023; 11:1501. [PMID: 37766177 PMCID: PMC10535203 DOI: 10.3390/vaccines11091501] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2023] [Revised: 09/05/2023] [Accepted: 09/07/2023] [Indexed: 09/29/2023] Open
Abstract
In vaccine efficacy trials, inaccurate counting of infection cases leads to systematic under-estimation-or "dilution"-of vaccine efficacy. In particular, if a sufficient fraction of observed cases are false positives, apparent efficacy will be greatly reduced, leading to unwarranted no-go decisions in vaccine development. Here, we propose a range of replicate testing strategies to address this problem, considering the additional challenge of uncertainty in both infection incidence and diagnostic assay specificity/sensitivity. A strategy that counts an infection case only if a majority of replicate assays return a positive result can substantially reduce efficacy dilution for assays with non-systematic (i.e., "random") errors. We also find that a cost-effective variant of this strategy, using confirmatory assays only if an initial assay is positive, yields a comparable benefit. In clinical trials, where frequent longitudinal samples are needed to detect short-lived infections, this "confirmatory majority rule" strategy can prevent the accumulation of false positives from magnifying efficacy dilution. When widespread public health screening is used for viruses, such as SARS-CoV-2, that have non-differentiating features or may be asymptomatic, these strategies can also serve to reduce unneeded isolations caused by false positives.
Collapse
Affiliation(s)
- Daniel I. S. Rosenbloom
- Quantitative Pharmacology and Pharmacometrics, Merck & Co., Inc., Rahway, NJ 07065, USA; (D.I.S.R.); (C.D.); (N.M.)
| | - Julie Dudášová
- Quantitative Pharmacology and Pharmacometrics, MSD Czech Republic, 15000 Prague, Czech Republic
- First Faculty of Medicine, Charles University, 12108 Prague, Czech Republic
| | - Casey Davis
- Quantitative Pharmacology and Pharmacometrics, Merck & Co., Inc., Rahway, NJ 07065, USA; (D.I.S.R.); (C.D.); (N.M.)
| | - Radha A. Railkar
- Biostatistics and Research Decision Sciences, Merck & Co., Inc., Rahway, NJ 07065, USA
| | - Nitin Mehrotra
- Quantitative Pharmacology and Pharmacometrics, Merck & Co., Inc., Rahway, NJ 07065, USA; (D.I.S.R.); (C.D.); (N.M.)
| | - Jeffrey R. Sachs
- Quantitative Pharmacology and Pharmacometrics, Merck & Co., Inc., Rahway, NJ 07065, USA; (D.I.S.R.); (C.D.); (N.M.)
| |
Collapse
|
4
|
Maas BM, Lommerse J, Plock N, Railkar RA, Cheung SYA, Caro L, Chen J, Liu W, Zhang Y, Huang Q, Gao W, Qin L, Meng J, Witjes H, Schindler E, Guiastrennec B, Bellanti F, Spellman DS, Roadcap B, Kalinova M, Fok-Seang J, Catchpole AP, Espeseth AS, Stoch SA, Lai E, Vora KA, Aliprantis AO, Sachs JR. Forward and reverse translational approaches to predict efficacy of neutralizing respiratory syncytial virus (RSV) antibody prophylaxis. EBioMedicine 2021; 73:103651. [PMID: 34775220 PMCID: PMC8603022 DOI: 10.1016/j.ebiom.2021.103651] [Citation(s) in RCA: 23] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2021] [Revised: 09/29/2021] [Accepted: 10/12/2021] [Indexed: 11/25/2022] Open
Abstract
BACKGROUND Neutralizing mAbs can prevent communicable viral diseases. MK-1654 is a respiratory syncytial virus (RSV) F glycoprotein neutralizing monoclonal antibody (mAb) under development to prevent RSV infection in infants. Development and validation of methods to predict efficacious doses of neutralizing antibodies across patient populations exposed to a time-varying force of infection (i.e., seasonal variation) are necessary. METHODS Five decades of clinical trial literature were leveraged to build a model-based meta-analysis (MBMA) describing the relationship between RSV serum neutralizing activity (SNA) and clinical endpoints. The MBMA was validated by backward translation to animal challenge experiments and forward translation to predict results of a recent RSV mAb trial. MBMA predictions were evaluated against a human trial of 70 participants who received either placebo or one of four dose-levels of MK-1654 and were challenged with RSV [NCT04086472]. The MBMA was used to perform clinical trial simulations and predict efficacy of MK-1654 in the infant target population. FINDINGS The MBMA established a quantitative relationship between RSV SNA and clinical endpoints. This relationship was quantitatively consistent with animal model challenge experiments and results of a recently published clinical trial. Additionally, SNA elicited by increasing doses of MK-1654 in humans reduced RSV symptomatic infection rates with a quantitative relationship that approximated the MBMA. The MBMA indicated a high probability that a single dose of ≥ 75 mg of MK-1654 will result in prophylactic efficacy (> 75% for 5 months) in infants. INTERPRETATION An MBMA approach can predict efficacy of neutralizing antibodies against RSV and potentially other respiratory pathogens.
Collapse
Affiliation(s)
- Brian M Maas
- Merck & Co., Inc., 2000 Galloping Hill Rd, Kenilworth, NJ 07033, USA
| | - Jos Lommerse
- Certara, 100 Overlook Center STE 101, Princeton, NJ 08540, USA
| | - Nele Plock
- Certara, 100 Overlook Center STE 101, Princeton, NJ 08540, USA
| | - Radha A Railkar
- Merck & Co., Inc., 2000 Galloping Hill Rd, Kenilworth, NJ 07033, USA
| | - S Y Amy Cheung
- Certara, 100 Overlook Center STE 101, Princeton, NJ 08540, USA
| | - Luzelena Caro
- Merck & Co., Inc., 2000 Galloping Hill Rd, Kenilworth, NJ 07033, USA
| | - Jingxian Chen
- Merck & Co., Inc., 2000 Galloping Hill Rd, Kenilworth, NJ 07033, USA
| | - Wen Liu
- Merck & Co., Inc., 2000 Galloping Hill Rd, Kenilworth, NJ 07033, USA
| | - Ying Zhang
- Merck & Co., Inc., 2000 Galloping Hill Rd, Kenilworth, NJ 07033, USA
| | - Qinlei Huang
- Merck & Co., Inc., 2000 Galloping Hill Rd, Kenilworth, NJ 07033, USA
| | - Wei Gao
- Merck & Co., Inc., 2000 Galloping Hill Rd, Kenilworth, NJ 07033, USA
| | - Li Qin
- Certara, 100 Overlook Center STE 101, Princeton, NJ 08540, USA
| | - Jie Meng
- Certara, 100 Overlook Center STE 101, Princeton, NJ 08540, USA
| | - Han Witjes
- Certara, 100 Overlook Center STE 101, Princeton, NJ 08540, USA
| | | | | | | | - Daniel S Spellman
- Merck & Co., Inc., 2000 Galloping Hill Rd, Kenilworth, NJ 07033, USA
| | - Brad Roadcap
- Merck & Co., Inc., 2000 Galloping Hill Rd, Kenilworth, NJ 07033, USA
| | | | | | | | - Amy S Espeseth
- Merck & Co., Inc., 2000 Galloping Hill Rd, Kenilworth, NJ 07033, USA
| | - S Aubrey Stoch
- Merck & Co., Inc., 2000 Galloping Hill Rd, Kenilworth, NJ 07033, USA
| | - Eseng Lai
- Merck & Co., Inc., 2000 Galloping Hill Rd, Kenilworth, NJ 07033, USA
| | - Kalpit A Vora
- Merck & Co., Inc., 2000 Galloping Hill Rd, Kenilworth, NJ 07033, USA
| | | | - Jeffrey R Sachs
- Merck & Co., Inc., 2000 Galloping Hill Rd, Kenilworth, NJ 07033, USA.
| |
Collapse
|
5
|
Aliprantis AO, Wolford D, Caro L, Maas BM, Ma H, Montgomery DL, Sterling LM, Hunt A, Cox KS, Vora KA, Roadcap BA, Railkar RA, Lee AW, Stoch SA, Lai E. A Phase 1 Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety, Tolerability, and Pharmacokinetics of a Respiratory Syncytial Virus Neutralizing Monoclonal Antibody MK-1654 in Healthy Adults. Clin Pharmacol Drug Dev 2020; 10:556-566. [PMID: 33125189 DOI: 10.1002/cpdd.883] [Citation(s) in RCA: 26] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2020] [Accepted: 09/24/2020] [Indexed: 12/26/2022]
Abstract
Respiratory syncytial virus (RSV) is the leading cause of acute lower respiratory tract infection and related morbidity and mortality in infants. Passive immunization with an RSV-neutralizing antibody can provide rapid protection to this vulnerable population. Proof-of-concept for this approach has been demonstrated by palivizumab; however, the use of this antibody is generally restricted to the highest-risk infants due to monthly dosing requirements and its cost. To address the large unmet medical need for most infants, we are evaluating MK-1654, a fully human RSV-neutralizing antibody with half-life extending mutations targeting site IV of the fusion protein. In this 2-part, placebo-controlled, double-blind, first-in-human study, 152 healthy adults were randomized 3:1 to receive a single dose of MK-1654 or placebo in 5 cohorts (100 or 300 mg as an intramuscular dose or 300, 1000, or 3000 mg as an intravenous dose). Safety, pharmacokinetics, antidrug antibodies, and RSV serum-neutralizing antibody titers were evaluated through 1 year. MK-1654 serum concentrations increased proportionally with dose and resulted in corresponding elevations in RSV serum-neutralizing antibody titers. The antibody displayed a half-life of 73 to 88 days and an estimated bioavailability of 69% at the 300-mg dose. The overall safety profile of MK-1654 was similar to placebo, and treatment-emergent antidrug antibodies were low (2.6%) with no associated adverse events. These data support the continued development of MK-1654 for the prevention of RSV disease in infants.
Collapse
Affiliation(s)
| | | | | | | | - Hua Ma
- Merck & Co., Inc., Kenilworth, New Jersey, USA
| | | | | | | | - Kara S Cox
- Merck & Co., Inc., Kenilworth, New Jersey, USA
| | | | | | | | | | | | - Eseng Lai
- Merck & Co., Inc., Kenilworth, New Jersey, USA
| |
Collapse
|
6
|
Aliprantis AO, Shaw CA, Griffin P, Farinola N, Railkar RA, Cao X, Liu W, Sachs JR, Swenson CJ, Lee H, Cox KS, Spellman DS, Winstead CJ, Smolenov I, Lai E, Zaks T, Espeseth AS, Panther L. A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults. Hum Vaccin Immunother 2020; 17:1248-1261. [PMID: 33121346 DOI: 10.1080/21645515.2020.1829899] [Citation(s) in RCA: 64] [Impact Index Per Article: 16.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
Respiratory Syncytial Virus (RSV) causes lower respiratory tract infections that can be severe and sometimes fatal. The risk for severe RSV infection is highest in infants and older adults. A safe and effective RSV vaccine for older adults represents a serious unmet medical need due to higher morbidity and mortality in this age group. In this randomized, partially double-blind, placebo-controlled, phase 1 dose-escalation study, we evaluated the safety, tolerability and immunogenicity of an investigational messenger ribonucleic acid (mRNA) vaccine encoding the RSV fusion protein (F) stabilized in the prefusion conformation. The study was conducted in healthy younger adults (ages ≥18 and ≤49 years) and healthy older adults (ages ≥60 and ≤79 years). Participants received mRNA-1777 (V171) or placebo as a single intramuscular dose. For each dose level, three sentinel participants were administered open-label mRNA-1777 (V171). Seventy-two younger adults were randomized and administered 25, 100, or 200 µg mRNA-1777 (V171) or placebo, and 107 older adults were randomized and administered 25, 100, 200 or 300 µg mRNA-1777 (V171) or placebo. Primary objectives were safety and tolerability and secondary objectives included humoral and cell-mediated immunogenicity. All dose levels of mRNA-1777 (V171) were generally well tolerated and no serious adverse events related to the vaccine were reported. Immunization with mRNA-1777 (V171) elicited a humoral immune response as measured by increases in RSV neutralizing antibody titers, serum antibody titers to RSV prefusion F protein, D25 competing antibody titers to RSV prefusion F protein, and cell-mediated immune responses to RSV-F peptides.
Collapse
Affiliation(s)
| | | | - Paul Griffin
- QPharm, Herston, Australia.,The University of Queensland, Brisbane, Australia.,Mater Research Raymond Terrace, South Brisbane, Australia
| | | | | | - Xin Cao
- Merck & Co., Inc., Kenilworth, NJ, USA
| | - Wen Liu
- Merck & Co., Inc., Kenilworth, NJ, USA
| | | | | | | | | | | | | | | | - Eseng Lai
- Merck & Co., Inc., Kenilworth, NJ, USA
| | - Tal Zaks
- Moderna, Inc., Cambridge, MA, USA
| | | | | |
Collapse
|
7
|
Krug AW, Vaddady P, Railkar RA, Musser BJ, Cote J, Ederveen A, Krefetz DG, DeNoia E, Free AL, Morrow L, Chakravarthy MV, Kauh E, Tatosian DA, Kothare PA. Leveraging a Clinical Phase Ib Proof-of-Concept Study for the GPR40 Agonist MK-8666 in Patients With Type 2 Diabetes for Model-Informed Phase II Dose Selection. Clin Transl Sci 2017; 10:404-411. [PMID: 28727908 PMCID: PMC5593169 DOI: 10.1111/cts.12479] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2017] [Accepted: 05/15/2017] [Indexed: 12/11/2022] Open
Abstract
GPR40 mediates free fatty acid–induced insulin secretion in beta cells. We investigated the safety, pharmacokinetics, and glucose response of MK‐8666, a partial GPR40 agonist, after once‐daily multiple dosing in type 2 diabetes patients. This double‐blind, multisite, parallel‐group study randomized 63 patients (placebo, n = 18; 50 mg, n = 9; 150 mg, n = 18; 500 mg, n = 18) for 14‐day treatment. The results showed no serious adverse effects or treatment‐related hypoglycemia. One patient (150‐mg group) showed mild‐to‐moderate transaminitis at the end of dosing. Median MK‐8666 Tmax was 2.0–2.5 h and mean apparent terminal half‐life was 22–32 h. On Day 15, MK‐8666 reduced fasting plasma glucose by 54.1 mg/dL (500 mg), 36.0 mg/dL (150 mg), and 30.8 mg/dL (50 mg) more than placebo, consistent with translational pharmacokinetic/pharmacodynamic model predictions. Maximal efficacy for longer‐term assessment is projected at 500 mg based on exposure–response analysis. In conclusion, MK‐8666 was generally well tolerated with robust glucose‐lowering efficacy.
Collapse
Affiliation(s)
- A W Krug
- Merck & Co., Inc., Kenilworth, New Jersesy, USA
| | - P Vaddady
- Merck & Co., Inc., Kenilworth, New Jersesy, USA
| | - R A Railkar
- Merck & Co., Inc., Kenilworth, New Jersesy, USA
| | - B J Musser
- Merck & Co., Inc., Kenilworth, New Jersesy, USA
| | - J Cote
- Merck & Co., Inc., Kenilworth, New Jersesy, USA
| | | | - D G Krefetz
- PRA Health Sciences, Marlton, New Jersey, USA
| | - E DeNoia
- ICON Development Solutions, San Antonio, Texas, USA
| | - A L Free
- Pinnacle Research Group, Anniston, Alabama, USA
| | - L Morrow
- Profil Institute for Clinical Research, Chula Vista, California, USA
| | - M V Chakravarthy
- Merck & Co., Inc., Kenilworth, New Jersesy, USA.,Eli Lilly & Co., Lilly Corporate Center, Indianapolis, IN 46285, USA
| | - E Kauh
- Merck & Co., Inc., Kenilworth, New Jersesy, USA
| | | | - P A Kothare
- Merck & Co., Inc., Kenilworth, New Jersesy, USA
| |
Collapse
|
8
|
Beals CR, Railkar RA, Schaeffer AK, Levin Y, Kochba E, Meyer BK, Evans RK, Sheldon EA, Lasseter K, Lang N, Weinberg A, Canniff J, Levin MJ. Immune response and reactogenicity of intradermal administration versus subcutaneous administration of varicella-zoster virus vaccine: an exploratory, randomised, partly blinded trial. Lancet Infect Dis 2016; 16:915-22. [PMID: 27061887 DOI: 10.1016/s1473-3099(16)00133-x] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Received: 05/11/2015] [Revised: 02/15/2016] [Accepted: 02/26/2016] [Indexed: 01/10/2023]
Abstract
BACKGROUND The licensed live, attenuated varicella-zoster virus vaccine prevents herpes zoster in adults older than 50 years. We aimed to determine whether intradermal administration of zoster vaccine could enhance vaccine immunogenicity compared with conventional needle subcutaneous administration. METHODS In this randomised, dose-ranging study, adults aged 50 years or older who had a history of varicella or who had resided in a country with endemic varicella-zoster virus infection for 30 years or more were eligible. Participants received the approved full or a 1/3 dose of zoster vaccine given subcutaneously or one of four intradermal doses (full, 1/3, 1/10, or 1/27 dose) using the MicronJet600 device. The two subcutaneous doses and the four intradermal doses were randomised (1·5:1:1:1:1:1) by computer generated sequence with randomisation stratified by age (50-59 years or 60 years or older). The primary immunogenicity endpoint was the change from baseline in IgG antibody to varicella-zoster virus-specific glycoproteins (gpELISA) measured at 6 weeks. All patients were included in the primary and safety analyses. This study is registered with ClinicalTrials.gov, number NCT01385566. FINDINGS Between Sept 2, 2011, and Jan 13, 2012, 224 participants were enrolled from three clinics in the USA and 223 were randomly assigned: 52 to receive the full dose subcutaneous zoster vaccine, 34 to receive the 1/3 dose subcutaneous zoster vaccine, 34 to receive the full dose intradermal zoster vaccine, 35 to receive the 1/3 dose intradermal zoster vaccine, 34 to receive the 1/10 dose intradermal zoster vaccine, and 34 to receive the 1/27 dose intradermal zoster vaccine. Full dose zoster vaccine given subcutaneously resulted in a gpELISA geometric mean fold-rise (GMFR) of 1·74 (90% CI 1·48-2·04) at 6 weeks post-vaccination compared with intradermal administration which resulted in a significantly higher gpELISA GMFR of 3·25 (2·68-3·94; p<0·0001), which also remained high at 18 months. An apparent dose-response relation was observed with intradermal administration (1/3 dose subcutaneous GMFR 1·64 [90% CI 1·36-1·99], 1/3 dose intradermal 2·58 (2·13-3·13), 1/10 dose intradermal 2·22 [1·83-2·69], and 1/27 dose intradermal 1·64 [1·35-2·00]). Each partial dose of zoster vaccine given intradermaly had a gpELISA GMFR comparable to that of full dose zoster vaccine given subcutaneously. Transient erythema and induration were more common after intradermal administration (31% erythema for full subcutaneous dose and 77% for intradermal dose). INTERPRETATION Intradermal zoster vaccine showed a greater increase in varicella-zoster virus gpELISA antibody compared with subcutaneous zoster vaccine at comparable doses. Larger and longer studies of intradermal administration of live, attenuated zoster vaccine are needed to provide convincing evidence of improved cell mediated immunity. FUNDING Merck & Co Inc.
Collapse
Affiliation(s)
| | | | | | - Yotam Levin
- NanoPass Technologies Ltd, Nes Ziona, Israel
| | | | | | | | | | | | - Nancy Lang
- Pediatric Infectious Diseases, University of Colorado, Denver Anschutz Medical Campus, Aurora, CO, USA
| | - Adriana Weinberg
- Pediatric Infectious Diseases, University of Colorado, Denver Anschutz Medical Campus, Aurora, CO, USA
| | - Jennifer Canniff
- Pediatric Infectious Diseases, University of Colorado, Denver Anschutz Medical Campus, Aurora, CO, USA
| | - Myron J Levin
- Pediatric Infectious Diseases, University of Colorado, Denver Anschutz Medical Campus, Aurora, CO, USA
| |
Collapse
|
9
|
Tanis KQ, Podtelezhnikov AA, Blackman SC, Hing J, Railkar RA, Lunceford J, Klappenbach JA, Wei B, Harman A, Camargo LM, Shah S, Finney EM, Hardwick JS, Loboda A, Watters J, Bergstrom DA, Demuth T, Herman GA, Strack PR, Iannone R. An accessible pharmacodynamic transcriptional biomarker for notch target engagement. Clin Pharmacol Ther 2016; 99:370-80. [DOI: 10.1002/cpt.335] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2015] [Revised: 12/21/2015] [Accepted: 12/23/2015] [Indexed: 01/27/2023]
Affiliation(s)
- KQ Tanis
- Merck & Co., Kenilworth; New Jersey USA
| | | | | | - J Hing
- Merck & Co., Kenilworth; New Jersey USA
| | | | | | | | - B Wei
- Merck & Co., Kenilworth; New Jersey USA
| | - A Harman
- Merck & Co., Kenilworth; New Jersey USA
| | | | - S Shah
- Merck & Co., Kenilworth; New Jersey USA
| | - EM Finney
- Merck & Co., Kenilworth; New Jersey USA
| | | | - A Loboda
- Merck & Co., Kenilworth; New Jersey USA
| | - J Watters
- Merck & Co., Kenilworth; New Jersey USA
| | | | - T Demuth
- Merck & Co., Kenilworth; New Jersey USA
| | - GA Herman
- Merck & Co., Kenilworth; New Jersey USA
| | - PR Strack
- Merck & Co., Kenilworth; New Jersey USA
| | - R Iannone
- Merck & Co., Kenilworth; New Jersey USA
| |
Collapse
|
10
|
Shankar SS, Shankar RR, Railkar RA, Beals CR, Steinberg HO, Kelley DE. Early Clinical Detection of Pharmacologic Response in Insulin Action in a Nondiabetic Insulin-Resistant Population. Curr Ther Res Clin Exp 2015; 77:83-9. [PMID: 26543510 PMCID: PMC4589823 DOI: 10.1016/j.curtheres.2015.08.001] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/07/2015] [Indexed: 11/16/2022] Open
Abstract
Background Insulin resistance heightens the risk for type 2 diabetes mellitus and cardiovascular disease. Amelioration of insulin resistance may reduce this risk. The thiazolidinedone class of insulin sensitizers improves insulin action in individuals with insulin-resistant diabetes and nondiabetic individuals. However, there are few reports on the time of onset of such effects independent of reversal of glucotoxicity. Objective The goal of our study was to test whether the thiazolidinedione pioglitazone has prominent early metabolic effects that can be detected in an obese, nondiabetic, insulin-resistant population. Methods We conducted a randomized, double-blind, placebo-controlled, parallel-group trial in men with nondiabetic insulin resistance using a hyperinsulinemic euglycemic clamp technique (at low and high doses of insulin at 10 and 40 mU/m2/min, respectively). The patients were given 30 mg daily oral pioglitazone or placebo for 28 days. Patients underwent a baseline clamp before initiation of treatment, and again at 14 and 28 days of treatment. Results Compared with placebo, under high-dose hyperinsulinemia, pioglitazone led to significant increases in glucose disposal rates (GDR) of 1.29 mg/kg/min (90% CI, 0.43–2.15; 39%; P=0.008) that were detectable at 2 weeks of treatment and persisted at 4 weeks of treatment. Under low-dose hyperinsulinemia, significant increases in GDR of 0.40 mg/kg/min (90% CI, 0.17–0.62; 95%; P=0.003) were observed at 4 weeks of treatment. These responses were accompanied by robust suppression of free fatty acids under hyperinsulinemic conditions, and by significant increases in circulating basal total adiponectin at 2 and 4 weeks of treatment. Conclusions Significant changes in insulin action across multiple insulin-sensitive tissues can be detected within 2 weeks of initiation of insulin-sensitizing therapy with pioglitazone in obese patients with nondiabetic insulin resistance. ClinicalTrials.gov identifier: NCT01115712.
Collapse
Affiliation(s)
- Sudha S Shankar
- Merck Research Laboratories, Merck & Co., Inc., Kenilworth, NJ
| | - R Ravi Shankar
- Merck Research Laboratories, Merck & Co., Inc., Kenilworth, NJ
| | - Radha A Railkar
- Merck Research Laboratories, Merck & Co., Inc., Kenilworth, NJ
| | - Chan R Beals
- Merck Research Laboratories, Merck & Co., Inc., Kenilworth, NJ
| | | | - David E Kelley
- Merck Research Laboratories, Merck & Co., Inc., Kenilworth, NJ
| |
Collapse
|
11
|
Blackman SC, Klappenbach JA, Railkar RA, Tanis K, Podtelezhnikov A, Loboda A, Dai X, Hing J, Stone J, Harman A, Hardwick J, Iannone R, Bergstrom D. Abstract B41: Identification of a time‐ and dose‐responsive transcriptional signature of Notch pathway inhibition in plucked human hair follicles following exposure to the gamma‐secretase inhibitor MK‐0752. Biomarkers 2014. [DOI: 10.1158/1535-7163.targ-09-b41] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
12
|
Schmidt EV, Blackman S, Iannone R, Senderak ET, Railkar RA, Evelhoch JL, Mozley PD, Perez EA, McDonough M, Rimawi M, Tolaney S, Kim SB, Chung HC. Abstract P4-01-11: Limits of [18F]-FLT PET as a clinical biomarker of proliferation in breast cancer. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p4-01-11] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:
Imaging biomarkers of cellular division offer promise as non-invasive measures of tumor response. 3’-deoxy-3’[18F]-fluorothymidine ([18F]-FLT) positron emission tomography (PET) imaging generally correlates with pathology-based measurements of cancer proliferation, especially the Ki67 score. Though clinical studies have associated changes in [18F]-FLT uptake with therapeutic response, clinical studies validating its ability to assess cell proliferation are comparatively lacking. The goal of this study was to determine quantitative relationships between [18F]-FLT compared with molecular and cellular metrics of proliferation during treatment for locally advanced breast cancer (LABC).
Methods:
Baseline [18F]−FLT-PET scans were obtained prior to the initiation of chemotherapy for LABC from patients enrolled at several academic oncology study sites. MRI scans, and transmission CT scans were obtained. Core needle biopsies were obtained to determine Ki-67 indices using immuno-histochemistry and to assess an mRNA signature based measurement of proliferation. Prospectively specified quantitative relationships between PET, Ki67 immunohistochemistry and the mRNA signature were evaluated using image-matched tumor specimens. Correlations between volumetric MRI changes and pathologic responses were evaluated in a post-hoc exploratory analysis.
Results:
Motivated by the hypothesis that effective chemotherapies should decrease tumor cell proliferation, FLT-PET was compared with biomarkers of proliferation including Ki67 and the mRNA signature during neoadjuvant treatment for LABC. [18F]-FLT correlated both with the Ki67 labeling index (SUVmean r = 0.53) and with the proliferation signature (SUVmean r = 0.7), validating the principle of thymidine analogue imaging. However, variability in the [18F]-FLT PET and tumor cell proliferation measures likely contributed to correlations less than pre-specified target values considered appropriate for clinical use (r > 0.78). Moreover, none of the proliferation biomarkers predicted pathologic complete responses at the end of neoadjuvant therapy ∼16 weeks after the 3 week response scan. In contrast, an evaluation of change in tumor volume measured by MRI after 3 weeks of therapy confirmed its superior ability to predict pCR and tumor re-staging.
Conclusion:
With large numbers of cancer drugs entering therapeutic pipelines, early efficacy measures remain critical for drug development. The 3-4 month neoadjuvant treatment paradigm for LABC offers unique opportunities for drug evaluation. Functional imaging using [18F]-FLT has been advanced as an assessor of cellular proliferation, potentially offering a non-invasive approach to response evaluation. While [18F]-FLT generally correlated with proliferation, its lack of association with patient responses likely limit its clinical utility. On the other hand, the predictive value of MRI offers unique opportunities for future trial designs and confirms previous reports (1).
1. N. M. Hylton et al., Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy. Radiology 263, 663 (2012).
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P4-01-11.
Collapse
Affiliation(s)
- EV Schmidt
- Merck Research Labs, Whitehouse Station, NJ; Seattle Genetics, Seattle, WA; Cornell Medical College, New York City, NY; Mayo Clinic Jacksonville, Jacksonville, FL; Baylor College of Medicine, Houston, TX; Dana Farber Cancer Institute, Boston, MA; Asan Medical Center, Seoul, Song-Pa, Korea; Yonsei University, Seoul, Seodaemun-gu, Korea
| | - S Blackman
- Merck Research Labs, Whitehouse Station, NJ; Seattle Genetics, Seattle, WA; Cornell Medical College, New York City, NY; Mayo Clinic Jacksonville, Jacksonville, FL; Baylor College of Medicine, Houston, TX; Dana Farber Cancer Institute, Boston, MA; Asan Medical Center, Seoul, Song-Pa, Korea; Yonsei University, Seoul, Seodaemun-gu, Korea
| | - R Iannone
- Merck Research Labs, Whitehouse Station, NJ; Seattle Genetics, Seattle, WA; Cornell Medical College, New York City, NY; Mayo Clinic Jacksonville, Jacksonville, FL; Baylor College of Medicine, Houston, TX; Dana Farber Cancer Institute, Boston, MA; Asan Medical Center, Seoul, Song-Pa, Korea; Yonsei University, Seoul, Seodaemun-gu, Korea
| | - ET Senderak
- Merck Research Labs, Whitehouse Station, NJ; Seattle Genetics, Seattle, WA; Cornell Medical College, New York City, NY; Mayo Clinic Jacksonville, Jacksonville, FL; Baylor College of Medicine, Houston, TX; Dana Farber Cancer Institute, Boston, MA; Asan Medical Center, Seoul, Song-Pa, Korea; Yonsei University, Seoul, Seodaemun-gu, Korea
| | - RA Railkar
- Merck Research Labs, Whitehouse Station, NJ; Seattle Genetics, Seattle, WA; Cornell Medical College, New York City, NY; Mayo Clinic Jacksonville, Jacksonville, FL; Baylor College of Medicine, Houston, TX; Dana Farber Cancer Institute, Boston, MA; Asan Medical Center, Seoul, Song-Pa, Korea; Yonsei University, Seoul, Seodaemun-gu, Korea
| | - JL Evelhoch
- Merck Research Labs, Whitehouse Station, NJ; Seattle Genetics, Seattle, WA; Cornell Medical College, New York City, NY; Mayo Clinic Jacksonville, Jacksonville, FL; Baylor College of Medicine, Houston, TX; Dana Farber Cancer Institute, Boston, MA; Asan Medical Center, Seoul, Song-Pa, Korea; Yonsei University, Seoul, Seodaemun-gu, Korea
| | - PD Mozley
- Merck Research Labs, Whitehouse Station, NJ; Seattle Genetics, Seattle, WA; Cornell Medical College, New York City, NY; Mayo Clinic Jacksonville, Jacksonville, FL; Baylor College of Medicine, Houston, TX; Dana Farber Cancer Institute, Boston, MA; Asan Medical Center, Seoul, Song-Pa, Korea; Yonsei University, Seoul, Seodaemun-gu, Korea
| | - EA Perez
- Merck Research Labs, Whitehouse Station, NJ; Seattle Genetics, Seattle, WA; Cornell Medical College, New York City, NY; Mayo Clinic Jacksonville, Jacksonville, FL; Baylor College of Medicine, Houston, TX; Dana Farber Cancer Institute, Boston, MA; Asan Medical Center, Seoul, Song-Pa, Korea; Yonsei University, Seoul, Seodaemun-gu, Korea
| | - M McDonough
- Merck Research Labs, Whitehouse Station, NJ; Seattle Genetics, Seattle, WA; Cornell Medical College, New York City, NY; Mayo Clinic Jacksonville, Jacksonville, FL; Baylor College of Medicine, Houston, TX; Dana Farber Cancer Institute, Boston, MA; Asan Medical Center, Seoul, Song-Pa, Korea; Yonsei University, Seoul, Seodaemun-gu, Korea
| | - M Rimawi
- Merck Research Labs, Whitehouse Station, NJ; Seattle Genetics, Seattle, WA; Cornell Medical College, New York City, NY; Mayo Clinic Jacksonville, Jacksonville, FL; Baylor College of Medicine, Houston, TX; Dana Farber Cancer Institute, Boston, MA; Asan Medical Center, Seoul, Song-Pa, Korea; Yonsei University, Seoul, Seodaemun-gu, Korea
| | - S Tolaney
- Merck Research Labs, Whitehouse Station, NJ; Seattle Genetics, Seattle, WA; Cornell Medical College, New York City, NY; Mayo Clinic Jacksonville, Jacksonville, FL; Baylor College of Medicine, Houston, TX; Dana Farber Cancer Institute, Boston, MA; Asan Medical Center, Seoul, Song-Pa, Korea; Yonsei University, Seoul, Seodaemun-gu, Korea
| | - S-B Kim
- Merck Research Labs, Whitehouse Station, NJ; Seattle Genetics, Seattle, WA; Cornell Medical College, New York City, NY; Mayo Clinic Jacksonville, Jacksonville, FL; Baylor College of Medicine, Houston, TX; Dana Farber Cancer Institute, Boston, MA; Asan Medical Center, Seoul, Song-Pa, Korea; Yonsei University, Seoul, Seodaemun-gu, Korea
| | - H-C Chung
- Merck Research Labs, Whitehouse Station, NJ; Seattle Genetics, Seattle, WA; Cornell Medical College, New York City, NY; Mayo Clinic Jacksonville, Jacksonville, FL; Baylor College of Medicine, Houston, TX; Dana Farber Cancer Institute, Boston, MA; Asan Medical Center, Seoul, Song-Pa, Korea; Yonsei University, Seoul, Seodaemun-gu, Korea
| |
Collapse
|
13
|
McLean MA, Sun A, Bradstreet TE, Schaeffer AK, Liu H, Iannone R, Herman G, Railkar RA, Joubert I, Gillard JH, Price SJ, Griffiths JR. Repeatability of edited lactate and other metabolites in astrocytoma at 3T. J Magn Reson Imaging 2012; 36:468-75. [PMID: 22535478 DOI: 10.1002/jmri.23673] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2011] [Accepted: 03/09/2012] [Indexed: 12/25/2022] Open
Abstract
PURPOSE To assess the repeatability of measurement of lactate and other metabolites in tumors using magnetic resonance spectroscopy (MRS). MATERIALS AND METHODS MRS with spectral editing for lactate was performed on 10 patients with astrocytoma (two Grade III, eight Grade IV) using an 8-channel receive coil at 3T. Lactate, lipid, choline, creatine, and N-acetyl aspartate (NAA) signals were measured in regions of tumor and contralateral white matter. Metabolites were quantified relative to unsuppressed water using LCModel fitting software. RESULTS The within-patient coefficients of variation were ≈16% (tumor lactate), 6%-8% (tumor choline and contralateral choline, creatine, and NAA), and 22% (tumor lipid). As expected due to their low concentration in normal tissue, lactate and lipid were not reliably detected in white matter but were found at high levels in most tumors. NAA and creatine were lower in tumors than in normal white matter, and choline varied between above- and below-normal values. No consistent short-term variation in metabolite levels was observed, despite differences in the time elapsed since administration of contrast agent. CONCLUSION MRS appears repeatable enough to provide longitudinal measures of metabolite content in tumors and contralateral tissue in the brain in vivo.
Collapse
Affiliation(s)
- Mary A McLean
- Cancer Research UK Cambridge Research Institute, Li Ka Shing Centre, Cambridge, UK.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Shire NJ, Yin M, Chen J, Railkar RA, Fox-Bosetti S, Johnson SM, Beals CR, Dardzinski BJ, Sanderson SO, Talwalkar JA, Ehman RL. Test-retest repeatability of MR elastography for noninvasive liver fibrosis assessment in hepatitis C. J Magn Reson Imaging 2011; 34:947-55. [PMID: 21751289 DOI: 10.1002/jmri.22716] [Citation(s) in RCA: 112] [Impact Index Per Article: 8.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2011] [Accepted: 06/17/2011] [Indexed: 12/11/2022] Open
Abstract
PURPOSE To conduct a rigorous evaluation of the repeatability of liver stiffness assessed by MR elastography (MRE) in healthy and hepatitis-C-infected subjects. MATERIALS AND METHODS A biopsy-correlated repeatability study using four-slice MRE was conducted in five healthy and four HCV-infected subjects. Subjects were scanned twice on day 1 and after 7-14 days. Each slice was acquired during a 14-s breath-hold with a commercially available acquisition technique (MR-Touch, GE Healthcare). Results were analyzed by two independent analysts. RESULTS The intraclass correlation coefficient (ICC) was 0.85 (90% confidence interval [CI]: 0.71 to 0.98) for the between-scan average of maximum stiffness within each slice and 0.88 (90% CI: 0.78 to 0.99) for the average of mean stiffness within each slice for the primary analyst. For both analysts, the average of the mean liver stiffness within each slice was highly reproducible with ICC of 0.93 and 0.94. Within-subject coefficients of variation ranged from 6.07% to 10.78% for HCV+ and healthy subjects. CONCLUSION MRE is a highly reproducible modality for assessing liver stiffness in HCV patients and healthy subjects and can discriminate between moderate fibrosis and healthy liver. MRE is a promising modality for noninvasive assessment of liver fibrosis (CLINICALTRIALS.GOV IDENTIFIER: NCT00896233).
Collapse
Affiliation(s)
- Norah J Shire
- Merck Sharp and Dohme Corp., Whitehouse Station, New Jersey, USA.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Blackman SC, Podtelezhnikov A, Railkar RA, Loboda A, Tanis K, Klappenbach JA, Watters J, Iannone R, Herman G, Bergstrom DA. Abstract 26: Notch pathway inhibition with MK-0752 leads to dose- and time-dependent transcriptional alterations in proliferation, PI3K, and Wnt pathway genes in plucked human hair follicles. Cancer Res 2010. [DOI: 10.1158/1538-7445.am10-26] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Gamma-secretase inhibitors (GSIs) inhibit Notch signaling and have potential as cancer therapeutics. A clinical trial of the oral GSI MK-0752 was conducted in healthy subjects using transcriptional profiling of human plucked hair follicles (PHFs). Data from this study were analyzed using pre-specified gene signatures reflecting Notch, proliferation, and PI3K pathway activity. De novo signature analysis was performed to identify late patterns of transcriptional response. Procedures: A randomized, placebo-controlled (PBO) trial evaluated the effects of a single 350mg or 1000mg dose of MK-0752 on PHF gene expression in healthy males. Plasma and pooled PHFs were collected for PK and PD (mRNA profiling) analyses. Results: In addition to a significant decrease in a Notch signature score (NSS, primary endpoint) which was maximal at 8.5h and significant up to 96h following a single 1000mg dose of MK-0752 compared to PBO, in a post hoc analysis we saw a significant decrease in a 101-gene Growth Factor Signature (GFS) score associated with downregulation of PI3K pathway signaling (effect size = −1.02, p < 0.001 1-sided) at 8.5h post-dose. In another post hoc analysis, we observed a significant suppression of a Proliferation Signature (PS) consisting of 50 cell cycle-associated genes (effect size = −0.57, p=0.016 1-sided) at 28.5h post-dose following a single 1000mg dose of MK-0752 compared to PBO. Dose- and time-dependent decreases were observed in both the GFS and the PS. To understand the compensatory transcriptional response at later time points, normalized data for each subject was compared to the corresponding time-point in the PBO-treated arm. In a training set, the paired t-test was used to identify 768 probes, representing genes that are strongly regulated (p < 0.005) 48-hours after treatment with MK-0752. Composite biomarker characteristics (a one-arm score, two-arm score, and AUC for the signature score in treated versus PBO groups) were calculated in validation set. Analysis of the most regulated genes at 48-hours post-dose showed significant changes in Wnt signaling and epithelial/mesenchymal transition (EMT) genes. Conclusions: Human PHFs contain cells with intact Notch signaling responsive to MK-0752. Transient inhibition of Notch leads to dose-dependent decreases in Notch and PI3K pathway genes, followed by decreases in cell cycle genes. As MK-0752 is eliminated and intrinsic Notch signaling re-established, we saw dose- and time-dependent upregulation of EMT and Wnt signaling, along with genes involved in cell communication and adhesion. These findings provide important evidence for cross-talk between Notch and other pathways relevant to oncology. These findings substantiate the rationale for combining PI3K pathway agents (e.g., an AKT or mTOR inhibitor) with a GSI for treatment of cancer.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 26.
Collapse
|
16
|
Abstract
The Mantel-Haenszel (M-H) procedure is commonly used to compare two treatments in a stratified binomial trial. However, this procedure is asymptotically optimal only if the odds ratio is constant across strata. We propose an alternative analytic strategy based on the simultaneous use of two statistics, ZS and ZI, each involving a weighted averaging of within-stratum differences between proportions. The two treatments are declared significantly different at overall level alpha if either min(ZS, ZI) > Zalpha/2 or max(ZS, ZI) > Zalpha*/2, where alpha* is data dependent. Our strategy is shown to be more powerful than the M-H and other related procedures. Numerical examples are provided for illustration.
Collapse
Affiliation(s)
- R A Railkar
- Department of Statistics, Temple University, Philadelphia, Pennsylvania 19122, USA
| | | | | |
Collapse
|